ATMPS Ltd has created the Hataali platform which digitises the end to end, cell and gene therapy process, providing immutable digital records with full chain of custody, identity and condition data. It can be used for clinical trials and commercially available therapies.

Hataali allows clinics, pharmaceutical companies, and couriers to communicate and coordinate their activities in real time. Hataali is modular and interoperable, integrating existing systems. It is patented and future-proof utilising blockchain technology.

Hospitals can digitally enrol and screen patients and order multiple treatments from multiple pharmaceutical companies through a single portal.

Pharmaceutical companies can easily administer, monitor and schedule treatments to multiple clinics in multiple countries, over one platform. Our digital analytics dashboards provide data driven decision making capabilities.

The Hataali platform significantly reduces implementation times and costs to users of the cell and gene therapy ecosystem. It increases efficiency, ensures patient safety and provides regulatory compliance.

Siemens Digital Industries (DI) is an innovation leader in automation and digitalization. Closely collaborating with partners and customers, DI drives the digital transformation. With its Digital Enterprise portfolio, DI provides companies of all sizes with an end-to-end set of products, solutions and services to integrate and digitalize the entire value chain. Optimized for the specific needs of each industry, DI’s unique portfolio supports customers to achieve greater productivity and flexibility. DI is constantly adding innovations to its portfolio to integrate cutting-edge future technologies. Siemens Digital Industries has its global headquarters in Nuremberg, Germany, and has around 76,000 employees internationally.

AGC Biologics is a global CDMO with seven facilities worldwide providing process development and manufacturing services for protein-based biologics and advanced therapies. From development to clinical trials, to full-scale commercialization, we can help you reach your goals at any stage in the development or manufacturing process. We specialize in the following modalities and substances, mammalian and microbial-based therapeutic proteins, recombinant DNA, plasmid DNA (pDNA), viral vectors, messenger RNA (mRNA), and genetically engineered cells. Our services range from Process Development, Analytical Development, cGMP Manufacturing (both clinical and commercial), Quality Control, and Quality Assurance and Process Validation.

Jobst Technologies Biosensors allow for the analysis of complex biological media. The detection of a large number of compounds is of great relevance, not only for scientific research but also for process and quality control. Pharmaceutical and biotechnology industries greatly desire frequent to continuous analysis of biological media. 

Jobst Technologies GmbH, an IST AG company, produces and develops biosensors designed to measure the concentration of parameters relevant for cell metabolism like glucose, lactate, glutamine, pyruvate and glutamate. The biosensors use the enzymatic-amperometric measurement principle. They are based on immobilized enzymes to detect the target analytes with high specificity and reliability. The biosensor construction enables the tuning of the measuring range, thus meeting the requirements of various applications and customers including CGT / ATM production. 

Our small and robust pre- calibrated biosensors are a key enabler in automated manufacturing equipment, offering analyzer quality metabolic monitoring in bio(pharma)-production.